Some patients with lymphoma show no detectable cancer by day 8 of treatment, and a lymphoma specialist explains how early testing could guide care.
|Articles|September 4, 2012
Personalized medicine in the genomic age of breast cancer
Author(s)Debu Tripathy
Advertisement
We're not going to find one drug to treat everyone. That's why molecular medicine, or personalized medicine, has become so important in treating breast cancer, in fact - all cancers. And like all cancers, there will not be a one-size fits all treatment. Watch Dr. Tripathy's latest video blog to learn more:
Advertisement
Related to this article
Life after cancer can bring lasting physical, financial and emotional challenges, especially for young survivors navigating life after treatment.
Dr. Maurie Markman discusses how AI could support primary care doctors and specialists caring for patients with cancer while keeping physicians at the center.
A combination of Zenbexus, Darzalex and dexamethasone nearly doubled the rate of deep, MRD-negative responses in relapsed multiple myeloma.
She was diagnosed with stage 4 primary mediastinal B-cell lymphoma (PMBCL), a type of non-Hodgkin lymphoma that starts in the center of the chest, at 29.
Jyoti Malhotra, MD, MPH on first-in-human clinical trials, lung cancer precision medicine in 2026, the disparities tension in drug development, and her move to Yale Cancer Center.
Dr. Maureen McEvoy explains breast cancer surgery options, reconstruction, recovery and how to close gaps in access to care.
For Blood Cancer Awareness Month, Dr. Guenther Koehne shares why immunotherapy is making this a promising time for people with blood cancers.
Advertisement
Advertisement